title: Is radical trachelectomy a safe alternative to radical hysterectomy for patients with stage IA-B carcinoma of the cervix?
abstract: BACKGROUND
  The prognosis associated with lymph node negative, early stage carcinoma of the cervix is excellent, with 5-year survival rates greater than 90%. Radical trachelectomy in combination with pelvic lymph node dissection (RVT + LPL) has emerged as an alternative to radical hysterectomy (RH) for these patients who desire preservation of fertility. However, there are limited data to support its efficacy and safety.
  
  
  METHODS
  All patient information was collected prospectively and was subsequently extracted from the cervical cancer surgery database of the Division of Gynecologic Oncology at the University of Toronto. Patients treated by RVT + LPL for fertility preservation were compared with two groups of patients treated by RH. One control group was matched for age, tumor size, histology, depth of invasion, presence of capillary lymphatic space involvement, lymph node metastases, and use of adjuvant radiation. The other control group consisted of patients with tumor sizes </=2 cm, negative pelvic lymph nodes who had not received adjuvant radiation therapy.
  
  
  RESULTS
  Thirty of 32 patients treated by RVT + LPL between March 1994 and November 1998 were matched. The only statistically significant difference in prognostic factors between the patients who underwent RVT + LPL and unmatched controls (556 patients) was the median depth of invasion in the adenocarcinomas (2. 0 mm vs. 4.0 mm, respectively; P < 0.02). The 2-year actuarial recurrence free survival was 95%, 100%, and 97% for the patients who underwent RVT + LPL, matched controls, and unmatched controls, respectively. The actuarial conception rate at 12 months was 37%.
  
  
  CONCLUSIONS
  Acknowledging the small numbers and short follow-up, RVT + LPL appears to be similar in efficacy to RH. If longer follow-up with more patients confirms the above, this procedure will represent an acceptable alternative to RH for patients with early Stage I carcinoma of the cervix who desire preservation of fertility.
authors.affiliation: Division of Gynecologic Oncology, Toronto-Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada.
authors.forename: A
authors.initials: A
authors.lastname: Covens
authors.forename: P
authors.initials: P
authors.lastname: Shaw
authors.forename: J
authors.initials: J
authors.lastname: Murphy
authors.forename: D
authors.initials: D
authors.lastname: DePetrillo
authors.forename: G
authors.initials: G
authors.lastname: Lickrish
authors.forename: S
authors.initials: S
authors.lastname: Laframboise
authors.forename: B
authors.initials: B
authors.lastname: Rosen
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D002584:Cervix Uteri / Q000601:surgery*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007247:Infertility, Female / Q000517:prevention & control; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000601:surgery*